ImmunoPrecise Antibodies Announces Restructuring of Management Team
ImmunoPrecise Antibodies (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics discovery and technology company, is excited to share several important leadership changes. Kamil Isaev has been appointed to the Company’s Board of Directors, and Joseph Scheffler has been named Interim Chief Financial Officer. Furthermore, IPA announces that Chris Buyse will be retiring from his position on the Board of Directors.
ImmunoPrecise Antibodies (IPA) is excited to announce significant leadership changes, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as the company’s Interim Chief Financial Officer. In addition, IPA shares that Chris Buyse will be retiring from the Board after making valuable contributions during his tenure.
Kamil Isaev Joins IPA’s Board of Directors
IPA is pleased to welcome Kamil Isaev, a seasoned technology executive and project strategist, to its Board of Directors. Isaev brings over 30 years of experience in AI, semiconductor technologies, and global R&D operations. Throughout his career, he has held leadership roles at Intel, Dell EMC, Align Technology, and ABRT VC, where he was responsible for driving innovation, scaling R&D centers, and leading high-impact cross-functional teams to commercialize emerging technologies.
Isaev is currently a Venture Partner at ABRT VC, where he leads the ABRT AI Lab and the VC Score project. These initiatives focus on AI-driven valuation models that help investors identify high-potential startups. Isaev’s work at ABRT VC bridges cutting-edge AI research with go-to-market strategies, helping AI-driven companies refine their approach to scalability.
Prior to his role at ABRT VC, Isaev served at Intel Corporation, where he was Director of Developer Relations Engineering. In this capacity, he oversaw AI and software development teams and played a key role in AI compute optimization, GPU workload migration, and machine learning integration. Isaev also served as General Manager of Country R&D at Intel, where he managed software initiatives and the deployment of machine learning and deep learning solutions.
Isaev’s career also includes roles at Align Technology, where he led an R&D division of more than 600 engineers, driving digital transformation and Agile adoption across the enterprise. At Caresyntax, Isaev helped the company expand into the U.S. and develop AI-powered surgical intelligence solutions. He also led AI and healthcare solution architecture at Dell EMC, overseeing the transition from technology development to industry adoption.
An IEEE Fellow and a frequent speaker at conferences on AI and the semiconductor industry, Isaev holds an MSc and PhD in Physics from Moscow State University and is the author of over 30 scientific publications.
“We are thrilled to welcome Kamil to our Board of Directors,” said Jennifer Bath, President and CEO of IPA. “His deep expertise in AI, R&D, and commercialization of cutting-edge technologies will be invaluable as we continue to strengthen our AI-powered biologics platform. Kamil’s experience in developing go-to-market strategies will be critical as we work to accelerate the journey from innovation to commercial impact.”
Joseph Scheffler Appointed Interim Chief Financial Officer
IPA also announces the appointment of Joseph Scheffler as Interim Chief Financial Officer. Scheffler brings more than 20 years of experience in financial reporting, forecasting, and business strategy in public and multinational companies.
Before joining IPA, Scheffler served as Acting Corporate Controller at Nidec – Kinetek, where he was responsible for consolidated financial reporting for a $400 million global manufacturing company. His extensive background includes financial advisory for acquisitions and corporate strategy development, making him well-suited to oversee IPA’s financial operations.
“We are excited to have Joseph on board,” said Jennifer Bath. “His financial expertise and strategic insight will strengthen our financial strategy and support IPA’s continued growth.”
Scheffler holds an MBA in Finance and a Bachelor’s degree in Accounting from Loyola University Chicago. His experience in stakeholder engagement and financial strategy will be crucial in guiding IPA during this phase of growth.
Chris Buyse Steps Down from IPA’s Board
IPA also announces that Chris Buyse will be stepping down from the Board of Directors after providing invaluable leadership during his tenure. “We are grateful to Chris for his contributions and financial leadership during this period of strategic evolution,” said Jennifer Bath. “His expertise has been critical to ensuring continuity as we prepare the company for its next phase of growth. We wish him every success.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics research and technology company focused on the discovery and development of AI-powered antibodies. The company provides an end-to-end solution for the development of next-generation therapeutic antibodies through its subsidiaries, Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) BV. IPA integrates systems biology, multiomics modeling, and artificial intelligence to discover highly specialized, fully human therapeutic antibodies for challenging disease targets. The company has a significant presence in the global healthcare landscape and is a leader in antibody discovery.
